ProPhase Labs, Inc. (PRPH)

US — Healthcare Sector
Peers: LMDX  STRR  ENZ  GTH  STIM  INBS  BDSX  PRPO  DRIO  OLK  XGN  SHC  BNR  PMD  SERA 

Automate Your Wheel Strategy on PRPH

With Tiblio's Option Bot, you can configure your own wheel strategy including PRPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PRPH
  • Rev/Share 0.3308
  • Book/Share 0.3593
  • PB 1.0687
  • Debt/Equity 3.3419
  • CurrentRatio 0.9534
  • ROIC -1.2009

 

  • MktCap 15951821.0
  • FreeCF/Share -0.9013
  • PFCF -0.8649
  • PE -0.1472
  • Debt/Assets 0.3888
  • DivYield 0
  • ROE -1.588

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript
PRPH
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Neutral

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2025 Earnings Conference Call May 20, 2025 10:00 AM ET Company Participants Noella Alexander-Young - Virtual Event Moderator, Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Hello, and good morning everyone. Welcome to today's presentation.

Read More
image for news ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript
Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now
PRPH
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Neutral

ProPhase Labs (PRPH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Read More
image for news Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
PRPH
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

New York, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on ProPhase's business model, services offered, industry outlook, financial results, management commentary, and risks.

Read More
image for news Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
PRPH
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company Announces Ongoing Strategic Cost Cutting to Focus Resources on new DTC Marketing Initiatives to Drive Growth and Profitability Dispels rumors of an Investment Bank initiating a Capital Raise GARDEN CITY, NY, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company provides a Company update and schedules a conference call for later today. Following the hiring of Stu Hollenshead, several new strategic opportunities have emerged for the Company to capitalize on its DTC multi-media expertise and infrastructure.

Read More
image for news ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables
PRPH
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, is focused on immediate cash generation through two key initiatives: strategic alternatives including a potential sale of its genomics assets and the aggressive collection of outstanding COVID-19 receivables. These initiatives are expected to generate significant liquidity starting in the next few months and strengthen the company's balance sheet.

Read More
image for news ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables
ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports
PRPH
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions.

Read More
image for news ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

About ProPhase Labs, Inc. (PRPH)

  • IPO Date 1994-04-04
  • Website https://www.prophaselabs.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Ted William Karkus
  • Employees 96

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.